1/40
Comprehensive practice flashcards detailing key terminology, signaling cascades, receptor pharmacology, and structural biology principles of GPCR and calcium second messenger signaling.
In calcium-mediated cellular responses what is needed for the release of Ca
Hormone stimulation leads to IP₃ production, which releases Ca²⁺ from
endoplasmic reticulum stores
example of Calcium-mediated cellular responses (picture)

Phospholipase C (PLC) activated by GP couple receptors
An enzyme activated by GPCRs that cleaves the membrane lipid PIP2 into two second messengers: IP3 and DAG.
Inositol 1,4,5-trisphosphate (IP3)
A water-soluble second messenger produced by PIP2 cleavage that diffuses through the cytoplasm to bind ER receptors and trigger the rapid release of stored Ca2+.
Diacylglycerol (DAG)
A lipid-derived second messenger generated by PLC cleavage that remains anchored in the plasma membrane to activate Protein Kinase C (PKC).
Protein Kinase C (PKC)
A kinase that translocates to the plasma membrane upon intracellular Ca2+ elevation
activated by DAG, Ca 2+ and phosphatidylserine to phosphorylate serine and threonine residues.
what occurs during IP3-mediated Calcium release
IP3 binds to IP3 receptors on the ER membrane, opening channels to rapidly release stored Ca2+
The surge in cytoplasmic Ca2+ activates calcium-binding proteins, such as calmodulin, which then regulate enzymes, ion channels, and cytoskeletal proteins.

Voltage-Dependent Anion Channels (VDACs) - CA2+ related
Outer mitochondrial membrane channels physically linked to ER IP3Rs via GRP75 proteins that transfer released Ca2+ from mitochondria-associated membranes (MAMs) into the intermembrane space.
Mitochondrial Ca2+ Uniporter (MCU)
An inner mitochondrial membrane channel opened by high Ca2+ concentrations in the intermembrane space, allowing Ca2+ to enter the mitochondrial matrix and stimulate ATP synthesis.
when Ca is too high in the matrix…
Step 4: Ca2+ - Released from matrix into the intermembrane space over time by inner membrane (NCLX) and Ca2+/H+ (HCX) antiporters to prevent Ca2+ toxicity. VDAC transfers intermembrane space Ca2+ into the cytosol.
Step 5: ER membrane Ca2+-ATPases pump Ca2+ from the cytosol into the ER – restores high ER Ca2+

STIM1 - opening of store-operated Ca2+
An ER transmembrane protein with luminal EF hand domains that senses ER Ca2+ levels;
binding of STIM1 to EB1 traps the STMI1
as ER stores are depleted it dissociates from EB1, oligomerizes, and migrates to ER-plasma membrane junctions.
Orai1
A store-operated Ca2+ channel located in the plasma membrane that is opened by the CAD domains of oligomerized STIM1 to permit extracellular Ca2+ into the cytosol.
Glycogen Phosphorylase Kinase (GPK)
A regulatory metabolic enzyme coordinated synergistically by both hormonal signals (cAMP via PKA) and neural/vasopressin signals (Ca2+ via calmodulin subunits) to stimulate glycogen breakdown.

side note: are GPCRS integral proteins and are they the largest family of membrane receptors?
yes
Orthosteric Binding Site (OBS) - activation of most GPCRS
The primary endogenous ligand-binding pocket of a GPCR that mediates receptor activation and stabilizes its active conformation.
other ways of GPCR activation (ligand independent)
light induced isomerizatioon (rhodospins)
proteolytic cleavage (PARs)
biophysical processes (pH)
Inverse Agonist - GPCR Ligand Classification
A ligand that decreases or abolishes basal constitutive GPCR signaling activity by stabilizing the receptor in an inactive conformation.
orthosteric ligands vs allosteric ligands
Orthosteric ligands binds directly to the primary active site whereas Allosteric ligands bind away from active site

Biased Agonism
The ability of specific ligands to selectively engage distinct downstream signaling pathways (such as G protein activation over β-arrestin recruitment) at the expense of others.
Oliceridine
A G protein-biased agonist targeting the μ-opioid receptor that actiates G protein signalling and minimizes β-arrestin signaling to produce analgesia with reduced adverse side effects like respiratory depression and constipation.
Oliceridine gives pain relief with reduced effects!
TRV027
A β -arrestin-biased agonist targeting the angiotensin II receptor (AT1R) that was evaluated in the BLAST-AHF trial for acute heart failure but discontinued after failing to surpass placebo efficacy.
Tachyphylaxis
A rapid decrease in receptor responsiveness following repeated or sustained agonist stimulation, presenting a key therapeutic obstacle in the treatment of chronic disorders.
when drugs stop working
Tachyphylaxis and Ligand-Receptor Kinetics
tachyphylaxis is primarily driven by the ligand's dissociation rate (koff) rather than β-arrestin-mediated desensitization.
High residence time agonists (low koff): Allow internalized receptors to remain active, promoting sustained signaling from endosomes.
Low residence time agonists: Dissociate during internalization, confining receptor activation to the plasma membrane and reducing tachyphylaxis.
Allosteric Modulators (AMs) - dealing with Tachypylaxis
Ligands that bind to to distinct sites, then the orthosteric binding site, fine-tuning the affinity or efficacy of orthosteric compounds with improved subtype specificity.
PAM vs NAM
PAM (Positive Allosteric Modulator) enhances the effects of orthosteric ligands
NAM (Negative Allosteric Modulator) reduces or inhibits their effects, creating a nuanced approach to pharmacological manipulation.
Cmpd-6
A positive allosteric modulator (PAM) of the β2-adrenergic receptor (β2AR) that amplifies agonist efficacy while reducing the susceptibility to receptor tachyphylaxis.
DETQ
A positive allosteric modulator (PAM) for the dopamine D1R that sustains locomotor activity over repeated administration without inducing the rapid tachyphylaxis caused by direct orthosteric agonists.
Biased Allosteric Modulators (BAMs)
Molecules that merge allosteric modulatory capability with selective signalling
results in tailored cell response with reduced adverse effects
SBI-553
A β-arrestin-biased allosteric modulator of the neurotensin 1 receptor (NTSR1) that promotes receptor internalization over Gq activation, eliminating side effects like hypothermia and hypotension.
Bitopic Ligand
ligans simultaneously occupy both the orthosteric binding site and an allosteric pocket on the same GPCR protomer to enhance affinity, selectivity, and residence time.
Tiotropium
A long-acting M3 antagonist prescribed for COPD that acts as a bitopic ligand by engaging both orthosteric and secondary binding sites simultaneously.
Bitopic ligand design (MOR)
Structural design of μ-opioid receptor (MOR) bitopic ligands involved linking a fentanyl moiety (orthosteric) to a guanidine group targeting the intramembrane sodium binding pocket (allosteric)
Bivalent Ligands
Dual-action compounds containing two distinct pharmacophoric moieties spaced by a linker to engage both protomers of a GPCR homodimer or heterodimer simultaneously.
GPCR Dimerization provides a mechanism for biased signaling and crosstalk regulation

Endomembrane Signaling
Localized GPCR signaling originating from intracellular membrane compartments (including endosomes, the Golgi complex, and mitochondria) following receptor internalization.
enables cells to have flexibility in downstream sustained signaling responses in both time and space
parathyroid hormone receptor was the first GPCR driven by endosomal siganling
Current models of GPCR signaling from endomembranes
PTH1R:
Internalized via β-arrestin
β-Arrestin stays bound at endosome to scaffold G protein
Drives sustained signaling; terminated by retromer
TSHR:
Internalized via ββ-arrestin; arrestin dissociates at endosome
Retromer mediates retrograde transport to Golgi/TGN
Activates second phase of signaling at Golgi
B2AR (β2AR):
β-arrestin engagement drives internalization
Initiates second phase of signaling from endosomes
Retromer rapidly recycles receptor to plasma membrane
B1AR (β1AR):
Localized at both plasma membrane and Golgi
Golgi activation requires no receptor trafficking
Activated at Golgi by ligands entering via transporters

Cell-Permeant Antagonists
Lipophilic or amphipathic receptor blockers capable of moving through membranes to suppress pathogenic GPCR signaling occurring from within intracellular compartments like endosomes.
Benefits of targeting internalized GPCRs
Block pathogen:
Prevent endosomal signalling with disorders
access intracellular Pools (target GPCRs with intracellular localization)
mitigate tachyphlaxis
traditional SAR vs dynamic SAR (structural Dynamics Structure - activity relationship)
Traditional SAR:Assumes a relatively static picture of a molecule or rigid ligand-receptor lock-and-key model
Dynamic SAR: Recognizes that molecules, proteins, and catalysts (such as nanoparticles) undergo conformational flexibility, induced-fit adjustments, or reaction-induced morphological changes during function.
Microswitches
Conserved networks of amino acid residues within GPCR helices that flip between inactive and active states
key structural determinants of allosteric regulation (3)
microswitches
allosteric ions → stabilize inactive conformation
membrane lipids
future perspective in drug delivery
